- Home
- MREO vs KZR Comparison
MREO vs KZR Comparison
Compare MREO & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | KZR |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 47.1M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MREO | KZR |
|---|---|---|
| Price | $0.33 | $7.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | $1.50 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.4M | 86.0K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $6,000.20 | N/A |
| Revenue Next Year | $34.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $3.53 |
| 52 Week High | $2.94 | $7.55 |
Technical Indicators
Market Signals| Indicator | MREO | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 62.76 |
| Support Level | $0.32 | $6.06 |
| Resistance Level | $0.42 | N/A |
| Average True Range (ATR) | 0.02 | 0.19 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 42.31 | 88.10 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.